Raymond S. Douglas

7.9k total citations · 1 hit paper
153 papers, 5.0k citations indexed

About

Raymond S. Douglas is a scholar working on Pathology and Forensic Medicine, Endocrinology, Diabetes and Metabolism and Neurology. According to data from OpenAlex, Raymond S. Douglas has authored 153 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Pathology and Forensic Medicine, 57 papers in Endocrinology, Diabetes and Metabolism and 50 papers in Neurology. Recurrent topics in Raymond S. Douglas's work include Ophthalmology and Eye Disorders (96 papers), Glaucoma and retinal disorders (39 papers) and Cerebral Venous Sinus Thrombosis (37 papers). Raymond S. Douglas is often cited by papers focused on Ophthalmology and Eye Disorders (96 papers), Glaucoma and retinal disorders (39 papers) and Cerebral Venous Sinus Thrombosis (37 papers). Raymond S. Douglas collaborates with scholars based in United States, Germany and China. Raymond S. Douglas's co-authors include Terry J. Smith, Robert A. Goldberg, Andrew G. Gianoukakis, Catherine J. Hwang, Shivani Gupta, Nikoo F. Afifiyan, Vibhavari Naik, George J. Kahaly, Nupur Raychaudhuri and Shanli Tsui and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Raymond S. Douglas

151 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017 492 citations Terry J. Smith, George J. Kahaly et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raymond S. Douglas United States	38	3.4k	2.2k	1.4k	1.4k	497	153	5.0k
Susanne Pitz Germany	29	1.4k 0.4×	876 0.4×	821 0.6×	529 0.4×	165 0.3×	84	2.8k
P. Martin van Hagen Netherlands	37	438 0.1×	509 0.2×	542 0.4×	573 0.4×	311 0.6×	134	3.6k
Jacqueline A. Leavitt United States	28	930 0.3×	301 0.1×	1.2k 0.8×	1.5k 1.1×	760 1.5×	89	3.2k
Edward G. Buckley United States	37	1.2k 0.4×	87 0.0×	2.9k 2.1×	1.2k 0.9×	335 0.7×	114	4.7k
Claudio Vitali Italy	26	825 0.2×	294 0.1×	129 0.1×	183 0.1×	1.5k 3.0×	59	5.0k
Shunsei Hirohata Japan	39	587 0.2×	50 0.0×	1.0k 0.7×	994 0.7×	157 0.3×	211	5.2k
F. Grisoli France	41	619 0.2×	1.1k 0.5×	161 0.1×	2.1k 1.6×	1.5k 3.0×	215	5.4k
Astrid Rasmussen United States	27	462 0.1×	184 0.1×	70 0.1×	486 0.4×	832 1.7×	76	4.1k
Alfonso Cerase Italy	31	400 0.1×	193 0.1×	251 0.2×	812 0.6×	619 1.2×	172	2.9k
Paolo Toti Italy	36	202 0.1×	647 0.3×	462 0.3×	85 0.1×	607 1.2×	155	4.1k

Countries citing papers authored by Raymond S. Douglas

Since Specialization

Citations

This map shows the geographic impact of Raymond S. Douglas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond S. Douglas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond S. Douglas more than expected).

Fields of papers citing papers by Raymond S. Douglas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond S. Douglas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond S. Douglas. The network helps show where Raymond S. Douglas may publish in the future.

Co-authorship network of co-authors of Raymond S. Douglas

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond S. Douglas. A scholar is included among the top collaborators of Raymond S. Douglas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond S. Douglas. Raymond S. Douglas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ugradar, Shoaib, et al.. (2024). Teprotumumab for the Treatment of Thyroid Eye Disease. Endocrine Reviews. 45(6). 843–857. 5 indexed citations

Ugradar, Shoaib, et al.. (2024). Clinical and Radiologic Predictors of Response to Teprotumumab: A 3D Volumetric Analysis of 35 Patients. Ophthalmic Plastic and Reconstructive Surgery. 41(4). 408–414. 2 indexed citations

Nichols, Kelly K., et al.. (2022). Topical Review: An Update of Diagnostic and Management Algorithms for Acquired Blepharoptosis. Optometry and Vision Science. 99(3). 230–240. 1 indexed citations

Douglas, Raymond S., Andrea L. Kossler, César A. Briceño, et al.. (2022). Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach. Journal of Neuro-Ophthalmology. 42(3). 334–339. 10 indexed citations

Douglas, Raymond S., Yao Wang, Roger A. Dailey, et al.. (2021). Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators. Journal of Neuro-Ophthalmology. 41(4). 461–468. 22 indexed citations

Azhdam, Ariel M., et al.. (2021). Angioleiomyoma of the nasolacrimal duct: case report and literature review. Orbit. 41(6). 783–785. 5 indexed citations

Wang, Yao, Tünde Mester, Shoaib Ugradar, & Raymond S. Douglas. (2021). Teprotumumab for the treatment of thyroid eye disease: Clinical experience from expanded access program (EAP). Investigative Ophthalmology & Visual Science. 62(8). 3339–3339. 2 indexed citations

Ugradar, Shoaib, et al.. (2020). Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. British Journal of Ophthalmology. 106(2). 165–171. 49 indexed citations

Ugradar, Shoaib, Lu Shi, Yao Wang, et al.. (2020). Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye. 35(9). 2607–2612. 38 indexed citations

10.

Ishii, Masaru, Halley Darrach, Kristin L. Bater, et al.. (2018). Objectively Measuring Observer Attention in Severe Thyroid‐Associated Orbitopathy: A 3D Study. The Laryngoscope. 129(5). 1250–1254. 5 indexed citations

11.

Hegedüs, László, Terry J. Smith, Raymond S. Douglas, & Claus Henrik Nielsen. (2011). Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. The Journal of Clinical Endocrinology & Metabolism. 74(1). 1–8. 4 indexed citations

12.

Padovani-Claudio, Dolly Ann, Roshini Fernando, Stephen Atkins, et al.. (2011). CD34+ Fibrocytes May Over-arch the Orbit and Thyroid in Patients with Graves’ Disease and Ophthalmopathy. Investigative Ophthalmology & Visual Science. 52(14). 5099–5099. 1 indexed citations

13.

Douglas, Raymond S., Vibhavari Naik, Catherine J. Hwang, et al.. (2008). B Cells from Patients with Graves’ Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis. The Journal of Immunology. 181(8). 5768–5774. 112 indexed citations

14.

Tsui, Shanli, Vibhavari Naik, Neil Hoa, et al.. (2008). Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves’ Disease. The Journal of Immunology. 181(6). 4397–4405. 282 indexed citations

15.

Zoumalan, Christopher I., Kimberly Cockerham, Roger E. Turbin, et al.. (2007). Efficacy of Corticosteroids and External Beam Radiation in the Management of Moderate to Severe Thyroid Eye Disease. Journal of Neuro-Ophthalmology. 27(3). 205–214. 29 indexed citations

16.

Douglas, Raymond S., Andrew G. Gianoukakis, Shweta Kamat, & Terry J. Smith. (2007). Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves’ Disease May Carry Functional Consequences for Disease Pathogenesis. The Journal of Immunology. 178(5). 3281–3287. 124 indexed citations

17.

Groth, Michael, et al.. (2006). Long-term Efficacy of Biomodeled Polymethyl Methacrylate Implants for Orbitofacial Defects. Archives of Facial Plastic Surgery. 8(6). 381–389. 20 indexed citations

18.

Taban, Mehryar, et al.. (2005). Efficacy of “Thick” Acellular Human Dermis (AlloDerm) for Lower Eyelid Reconstruction. Archives of Facial Plastic Surgery. 7(1). 38–44. 65 indexed citations

19.

Douglas, Raymond S. & Roberta E. Gausas. (2003). A Systematic Comprehensive Approach to Management of Irreversible Facial Paralysis. Facial Plastic Surgery. 19(1). 107–112. 8 indexed citations

20.

Myslobodsky, M., et al.. (1981). Sodium valproate reduction of photo convulsive responses effect or side effect. 17(5). 390. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact